This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Healthcare Decision Support And IBM Watson: Market Shares, Strategies, And Forecasts, Worldwide, 2013 To 2019

NEW YORK, March 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Healthcare Decision Support and IBM Watson: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019

http://www.reportlinker.com/p01140649/Healthcare-Decision-Support-and-IBM-Watson-Market-Shares-Strategies-and-Forecasts-Worldwide-2013-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Healthcare

Healthcare decision support markets consist of traditional market participants led by McKesson and Watson from IBM. IBM Watson offers structured and unstructured data in combination. This represents a major breakthrough in what kind of decision support can be offered.

IBM Watson can provide a far more differentiated testing assessment. Watson knows what tests are relevant to further characterize a particular patient condition and what tests are not.

It is a great help to physicians to have an assistant that is able to have read the latest journal articles and is loaded with medical information to recommend what tests may be relevant in a particular situation. Wrong tests, tests that are not useful in a particular situation, account for 30% of the costs of healthcare delivery in the US. This is a lot. To have a new system available that addresses these issues is great.

IBM Watson is initiating a new era of cognitive computing that extends the tabulator and application program intensive enabling new market opportunities based on cognitive performance. Watson is so powerful and so new that the uses for it are not even defined yet. The tools and methods released by natural language computing systems are remarkable. They are very exciting.

Watson is comprised of a core engine. This engine is more powerful than anything that has been designed by humans before. To the credit of IBM, the first purpose that Watson has been put to is to improve healthcare delivery. To those analysts following Watson, there is tremendous promise in the offing.

IBM concentrates on building end to end systems that are able to adapt of market changes. While this may make the IBM product set seem overly heavy in the short run, in the long run, this is of enormous value to clients as proved by the company market leading position in innovation software.

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs